The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.
D000588:Amines / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use; D002166:Camptothecin / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D002712:Chlorides / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D004357:Drug Synergism; D004640:Emetine / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D007659:Ketones / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D010879:Piperazines / Q000627:therapeutic use*; D010984:Platinum / Q000627:therapeutic use*; D011407:Propane / Q000627:therapeutic use; D013997:Time Factors
D000588:Amines; D000970:Antineoplastic Agents; D002712:Chlorides; D007659:Ketones; D010879:Piperazines; D003561:Cytarabine; D010984:Platinum; D003520:Cyclophosphamide; D001374:Azacitidine; D011407:Propane; D005472:Fluorouracil; D002330:Carmustine; D004640:Emetine; D002166:Camptothecin; D008727:Methotrexate